Compared with KLF7 silencing alone, the combined treatment elevated TPD52 expression (p < .01, Figure 4(b), enhanced cell viability (p < .01, Figure 4(c), and strengthened invasion and migration (p < .01, Figure 4(d–e), indicating that inhibiting miR-139-5p partially reversed the inhibitory effect of KLF7 silencing on CRC cells. Here, TPD52 is linked to colorectal carcinoma.